Dr. Reddy's Laboratories has entered into a definitive agreement with Haleon plc to acquire its consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category outside the United States. The acquisition, valued at 500 million pounds ($633 million), includes the global NRT brand Nicotinell and its local market-leading brands such as Nicabate. This strategic move is a significant step towards Dr. Reddy's goal of building a global consumer healthcare business. The acquisition is expected to generate GBP 217 million in revenues in 2023. G V Prasad, a representative of Dr. Reddy's, mentioned that the company had been pursuing this deal for a while.
ET NOW Exclusive | "We were pursuing Nicotinell deal for a while now" says G V Prasad of Dr Reddy's @drreddys @gvprasad @AASTHACHOPRA13 https://t.co/JytJBXaNrQ
Dr. Reddy's announces acquisition of nicotine replacement therapy brand Nicotinell, expected to generate GBP 217 million in revenues in 2023. #news #acquisition $HLN $RDY
Dr Reddy's Laboratories to acquire Nicotinell from Haleon — here’s why analysts are divided @ekta_batra @kanishka9996 https://t.co/qbMfS7cCOi
#DrReddy's to buy #nicotine #replacement brands from #UK-based #Haleon for $632 million https://t.co/rpQ94l3TYl
🇬🇧 Haleon sells off nicotine replacement brands for £500m https://t.co/AkrkE1waII
🇬🇧 Haleon quits nicotine replacement with £500m sale of brands https://t.co/1SzzaCakUY
Dr. Reddy's Laboratories: To acquire Nicotinell and related portfolio in a significant step towards building a global consumer healthcare business. The portfolio that will be acquired consists of global NRT brand Nicotinell and its local market-leading brands namely Nicabate,
Dr. Reddy’s to acquire Haleon’s global portfolio of consumer healthcare brands in Nicotine Replacement Therapy https://t.co/kiG3jDJqU8
Haleon reels in $633M with sale of ex-US nicotine replacement unit to Dr. Reddy's https://t.co/V1RQCd1fD8
Haleon will sell its nicotine replacement therapy business outside the U.S. to a unit of India's Dr. Reddy's for 500 million pounds ($632.55 million), the British consumer healthcare company said on Wednesday. https://t.co/CLzYS5mK5n https://t.co/CLzYS5mK5n
Haleon to sell nicotine replacement therapy business outside US for $633 mln https://t.co/xondzFoDqx https://t.co/5eDWuiwEE8
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business $RDY https://t.co/J8FCUts6Qz
Dr Reddy's to acquire Haleon's nicotine replacement therapy portfolio for 500 million pounds @jpullokaran https://t.co/muB6guTf4S
Dr Reddy's Concall | Enters into a definitive agreement with Haleon plc to acquire consumer healthcare brands in Nicotine Replacement Therapy (“NRT”) category, outside the US Here are the details of the deal, OTC biz, pipeline and more👇 @drreddys @haleon_health #StockMarket https://t.co/2R0X0t8KwX